The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Population PK/PD analysis of the pan-HDAC inhibitor resminostat.
Roland Baumgartner
Employment or Leadership Position - 4SC
Stock Ownership - 4SC
Stefan W. Henning
Employment or Leadership Position - 4SC
Stock Ownership - 4SC
Bernhard Hauns
Employment or Leadership Position - Director Development Projects
Astrid Ammendola
Employment or Leadership Position - 4SC
Babett Krauss
Employment or Leadership Position - 4SC
Stock Ownership - 4SC
Julia Holzapfel
Employment or Leadership Position - 4SC
Michael Bitzer
Consultant or Advisory Role - 4SC
Other Remuneration - 4SC
Bernd Hentsch
Employment or Leadership Position - 4SC
Stock Ownership - 4SC